Back to today’s briefing

Story perspectives

Inhibrx OX40 Immunotherapy Shows Head and Neck Cancer Responses

9/9/2026

21 2 Full Breakdown

Summary

Story summary

Inhibrx announced its experimental OX40 immunotherapy generated responses in head and neck cancer patients on Tuesday.
The therapy showed especially strong responses in a small group of patients with HPV-positive tumors.
Researchers warned that the HPV-positive subset could limit the drug’s broader applicability.
Pfizer, Genentech, GSK and AstraZeneca have unsuccessfully pursued OX40 targets for about 15 years.

1 of 1

Story summary

Inhibrx announced its experimental OX40 immunotherapy generated responses in head and neck cancer patients on Tuesday.
The therapy showed especially strong responses in a small group of patients with HPV-positive tumors.
Researchers warned that the HPV-positive subset could limit the drug’s broader applicability.
Pfizer, Genentech, GSK and AstraZeneca have unsuccessfully pursued OX40 targets for about 15 years.